Do analysts recommend BDRX or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, BDRX or ZVSA?

Biodexa Pharmaceuticals has higher revenue and earnings than ZyVersa Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 3.33 -$8.42M N/A N/A ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A

Is BDRX or ZVSA more profitable?

Biodexa Pharmaceuticals' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Biodexa Pharmaceuticals N/A N/A N/A ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts prefer CELZ or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CELZ or ZVSA more profitable?

Creative Medical Technology's return on equity of -86.52% beat ZyVersa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -86.52% -81.96% ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts rate PPCB or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, PPCB or ZVSA?

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A

Is PPCB or ZVSA more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts prefer GOVX or ZVSA?

GeoVax Labs currently has a consensus price target of $150.00, suggesting a potential upside of 20,791.36%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities research analysts clearly believe GeoVax Labs is more favorable than ZyVersa Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GOVX or ZVSA more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% ZyVersa Therapeutics N/A -109.54% -43.95%

Do analysts prefer BIAF or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

ZyVersa Therapeutics (ZVSA) Competitors

$0.10 0.00 (-2.27%)

As of 08/14/2026 02:19 PM Eastern

Compare

ZVSA vs. BDRX, CELZ, PPCB, GOVX, and BIAF

Should you buy ZyVersa Therapeutics stock or one of its competitors? ZyVersa Therapeutics's main competitors and comparable companies include Biodexa Pharmaceuticals (BDRX), Creative Medical Technology (CELZ), Propanc Biopharma (PPCB), GeoVax Labs (GOVX), and bioAffinity Technologies (BIAF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ZyVersa Therapeutics compare to Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Biodexa Pharmaceuticals had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 0 mentions for ZyVersa Therapeutics. Biodexa Pharmaceuticals' average media sentiment score of 0.44 beat ZyVersa Therapeutics' score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
ZyVersa Therapeutics	Neutral

Biodexa Pharmaceuticals' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Biodexa Pharmaceuticals has higher revenue and earnings than ZyVersa Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	3.33	-$8.42M	N/A	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

Biodexa Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Summary

Biodexa Pharmaceuticals beats ZyVersa Therapeutics on 10 of the 10 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Creative Medical Technology?

Creative Medical Technology (NASDAQ:CELZ) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Creative Medical Technology's return on equity of -86.52% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Creative Medical Technology has a beta of 1.94, meaning that its stock price is 94% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Creative Medical Technology has higher revenue and earnings than ZyVersa Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	803.98	-$5.99M	-$2.07	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

In the previous week, Creative Medical Technology had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 1 mentions for Creative Medical Technology and 0 mentions for ZyVersa Therapeutics. Creative Medical Technology's average media sentiment score of 1.90 beat ZyVersa Therapeutics' score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Overall Sentiment
Creative Medical Technology	Very Positive
ZyVersa Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Creative Medical Technology beats ZyVersa Therapeutics on 8 of the 12 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Propanc Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Propanc Biopharma had 4 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 4 mentions for Propanc Biopharma and 0 mentions for ZyVersa Therapeutics. Propanc Biopharma's average media sentiment score of 0.72 beat ZyVersa Therapeutics' score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Propanc Biopharma	Positive
ZyVersa Therapeutics	Neutral

Propanc Biopharma has a beta of 3.52, suggesting that its stock price is 252% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

3.9% of ZyVersa Therapeutics shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ZyVersa Therapeutics' return on equity of -109.54% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Summary

Propanc Biopharma beats ZyVersa Therapeutics on 6 of the 11 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to GeoVax Labs?

GeoVax Labs (NASDAQ:GOVX) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

GeoVax Labs currently has a consensus price target of $150.00, suggesting a potential upside of 20,791.36%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities research analysts clearly believe GeoVax Labs is more favorable than ZyVersa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GeoVax Labs has a beta of 3.73, meaning that its share price is 273% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

ZyVersa Therapeutics' return on equity of -109.54% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

ZyVersa Therapeutics has lower revenue, but higher earnings than GeoVax Labs. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49M	1.00	-$21.47M	-$11.34	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, GeoVax Labs had 5 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 5 mentions for GeoVax Labs and 0 mentions for ZyVersa Therapeutics. GeoVax Labs' average media sentiment score of 0.57 beat ZyVersa Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Overall Sentiment
GeoVax Labs	Positive
ZyVersa Therapeutics	Neutral

Summary

GeoVax Labs beats ZyVersa Therapeutics on 9 of the 13 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

In the previous week, bioAffinity Technologies had 8 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 8 mentions for bioAffinity Technologies and 0 mentions for ZyVersa Therapeutics. bioAffinity Technologies' average media sentiment score of 0.36 beat ZyVersa Therapeutics' score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
bioAffinity Technologies	Neutral
ZyVersa Therapeutics	Neutral

bioAffinity Technologies has a beta of -1.05, meaning that its stock price is 205% less volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ZyVersa Therapeutics has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. ZyVersa Therapeutics' return on equity of -109.54% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-257.30%	-220.52%	-136.76%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

ZyVersa Therapeutics has lower revenue, but higher earnings than bioAffinity Technologies. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16M	0.53	-$14.91M	-$7.30	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

ZyVersa Therapeutics beats bioAffinity Technologies on 7 of the 13 factors compared between the two stocks.

Get ZyVersa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVSA vs. The Competition

Export

Metric	ZyVersa Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$786K	$3.72B	$7.03B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.64%
P/E Ratio	-0.12	10.83	271.54	25.40
Price / Sales	N/A	1,360.21	673.88	125.76
Price / Cash	N/A	101.42	75.70	53.27
Price / Book	0.03	16.78	12.92	6.21
Net Income	-$9.41M	-$13.32M	$3.45B	$347.71M
7 Day Performance	N/A	1.76%	1.16%	1.08%
1 Month Performance	N/A	2.86%	2.17%	1.87%
1 Year Performance	N/A	54.10%	62.38%	20.79%

ZyVersa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVSA ZyVersa Therapeutics	N/A	$0.10 -2.3%	N/A	-35.9%	$786K	N/A	N/A	2	Upcoming Earnings Gap Up
BDRX Biodexa Pharmaceuticals	0.3418 of 5 stars	$1.47 -7.5%	N/A	-95.7%	$3.17M	$470K	N/A	20	Short Interest Increase
CELZ Creative Medical Technology	1.4036 of 5 stars	$1.15 +71.9%	N/A	-60.9%	$3.17M	$10K	N/A	5	Earnings Report Analyst Upgrade Gap Up High Trading Volume
PPCB Propanc Biopharma	1.1236 of 5 stars	$1.37 +16.1%	N/A	-98.3%	$2.69M	N/A	N/A	1	Analyst Upgrade Short Interest Decrease Gap Up High Trading Volume
GOVX GeoVax Labs	2.778 of 5 stars	$0.72 -2.8%	$150.00 +20,698.7%	-96.2%	$2.58M	$2.49M	N/A	10	News Coverage Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVSA) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. BDRX, CELZ, PPCB, GOVX, and BIAF

How does ZyVersa Therapeutics compare to Biodexa Pharmaceuticals?

Summary

How does ZyVersa Therapeutics compare to Creative Medical Technology?

Summary

How does ZyVersa Therapeutics compare to Propanc Biopharma?

Summary

How does ZyVersa Therapeutics compare to GeoVax Labs?

Summary

How does ZyVersa Therapeutics compare to bioAffinity Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. BDRX, CELZ, PPCB, GOVX, and BIAF

How does ZyVersa Therapeutics compare to Biodexa Pharmaceuticals?

Do analysts recommend BDRX or ZVSA?

Do institutionals and insiders believe in BDRX or ZVSA?

Does the media refer more to BDRX or ZVSA?

Is BDRX or ZVSA more profitable?

Which has stronger earnings & valuation, BDRX or ZVSA?

Which has more risk and volatility, BDRX or ZVSA?

Summary

How does ZyVersa Therapeutics compare to Creative Medical Technology?

Is CELZ or ZVSA more profitable?

Which has more volatility & risk, CELZ or ZVSA?

Do insiders and institutionals have more ownership in CELZ or ZVSA?

Which has stronger earnings & valuation, CELZ or ZVSA?

Does the media favor CELZ or ZVSA?

Do analysts prefer CELZ or ZVSA?

Summary

How does ZyVersa Therapeutics compare to Propanc Biopharma?

Which has preferable earnings & valuation, PPCB or ZVSA?

Do analysts rate PPCB or ZVSA?

Does the media prefer PPCB or ZVSA?

Which has more risk & volatility, PPCB or ZVSA?

Do insiders and institutionals hold more shares of PPCB or ZVSA?

Is PPCB or ZVSA more profitable?

Summary

How does ZyVersa Therapeutics compare to GeoVax Labs?

Do analysts prefer GOVX or ZVSA?

Which has more volatility and risk, GOVX or ZVSA?

Is GOVX or ZVSA more profitable?

Which has preferable earnings & valuation, GOVX or ZVSA?

Do institutionals & insiders believe in GOVX or ZVSA?

Does the media refer more to GOVX or ZVSA?

Summary

How does ZyVersa Therapeutics compare to bioAffinity Technologies?

Does the media refer more to BIAF or ZVSA?

Which has more risk & volatility, BIAF or ZVSA?

Do insiders & institutionals believe in BIAF or ZVSA?

Is BIAF or ZVSA more profitable?

Which has stronger valuation & earnings, BIAF or ZVSA?

Do analysts prefer BIAF or ZVSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools